高血压伴肾上腺增生58例临床分析The Clinical Analysis of Hypertension with Adrenal Hyperplasis in 58 patients
罗荔,徐新娟
摘要(Abstract)：
目的:探讨高血压伴肾上腺增生患者的临床特点。方法:对533例高血压患者进行肾上腺CT检查,根据CT显示肾上腺增生的高血压患者为试验组,共有58例,同时随机选取65例CT显示肾上腺正常的高血压患者为对照组,对2组患者的临床指标进行对比分析。结果:(1)在533例高血压患者中,伴肾上腺增生的有58例,占受检人群的10．88％。44例伴左侧肾上腺增生(75．86％),14例伴双侧肾上腺增生(24．14％)。至今未发现伴右侧肾上腺增生的高血压病患者。(2)试验组血钾水平显著低于对照组,差异有统计学意义(P<0．05)。(3)2组卧立位血浆肾素活性、血管紧张素Ⅱ、醛固酮水平、血钠、24 h尿钾、尿钠水平及收缩压和舒张压差异均无统计学意义, 但试验组的肾素活性、醛固酮水平、收缩压及舒张压水平均高于对照组。结论:高血压伴肾上腺增生患者中肾上腺增生大部分为左侧肾上腺增生,其增生的肾上腺可能有自主分泌功能,影响血压的调节。
关键词(KeyWords)： 高血压;肾上腺增生;肾素;血管紧张素;醛固酮
基金项目(Foundation):
作者(Author): 罗荔,徐新娟
参考文献(References)：
- [1] Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology[J]. Clin Endocrinol Metab,2000,85: 1863-1867.
- [2] McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin aldosterone axis, including primary hyperaldosteronism [J]. Clin Endocrinol Metab, 1991,73: 952-957.
- [3] Cortes P, Fardella C, Oestreicher E, et al. Excess of mineralocorticoids in essential hypertension: clinical-diagnostic ap proach[J]. Rev Med Chil, 2000,128:955-961.
- [4] Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio: a simple test for primary aldosteronism[J]. Acta Endocrinol (Copenhagen),1986, 113: 564-569.
- [5] Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma rennin activity ratio in primary aldosteronism [J]. Hypertension, 2002, 40: 897-902.
- [6]Seifarth C, Trenkel S, Schobel H, et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism[J]. Clin Endocrinol, 2002, 576:457-465.
- [7] Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis, and Management[M]. New York: Raven Press. 1995.1953-1967.
- [8]张雪林,郭启勇,吴恩惠,等．7年制医学影像学[M]．北京:人 民卫生出版社,2001.309．
- [9] Lim PO, Dow E, Brennan G, et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population [J]. Hum Hypertens,2000,14: 311-315.
- [10] Lorena M, Cristian C, Alexis G, et al. Primary Aldosteronism and Hypertensive Disease[J]. Hypertension, 2003,42: 161-165.
- [11] McMahon D, Graham T, Robert G, et al. Glucocorticoid Remediable Aldosteronism[J]. Cardiology in Review, 2004, 12(1):44-48.